CLDF Title
Home | Contact Us | Bookmark
About CLDF Centers of Educational Expertise  
Webcasts Slide Library Abstract Library Conference Highlights
Reuters Health Information (2011-03-04): FDA removes liver warning from Gilead drug


FDA removes liver warning from Gilead drug

Last Updated: 2011-03-04 13:37:21 -0400 (Reuters Health)

CHICAGO (Reuters) - U.S. health regulators removed warnings about potential liver damage from Gilead Sciences Inc's ambrisentan.

The drug, sold under the brand name Letairis, is a treatment to improve exercise ability and delay clinical worsening in patients with pulmonary arterial hypertension (PAH) and predominantly WHO Functional Class II-III symptoms.

Gilead said PAH patients receiving Letairis are no longer required to get monthly liver function tests.

On its website the company says the FDA decision was "based on its review of post-marketing data reflecting use of Letairis over more than 7,800 patient years.... During 12-week controlled clinical trials, the incidence of liver function abnormalities was 0% on Letairis and 2.3% on placebo."

Because of the risk of birth defects, Letairis continues to have a Boxed Warning.

Slide Library
Abstract Library
Slide Library
Abstract Library
Slide Library
Abstract Library
Slide Library
Abstract Library
CLDF Follow Us
About CLDF
Mission Statement
Board of Trustees
Board of Advisors
CLDF Supporters
Other Resources
Liver News Library
Journal Abstracts
Hep C Link to Care
Centers of
Educational Expertise
Regional Map
  The Chronic Liver Disease Foundation is a non-profit organization with content developed specifically for healthcare professionals.
© Copyright 2012-2015 Chronic Liver Disease Foundation. All rights reserved. This site is maintained as an educational resource for US healthcare providers only.
Use of this Web site is governed by the Chronic Liver Disease Foundation terms of use and privacy statement.